For the quarter ending 2025-09-30, RGEN had $39,892K increase in cash & cash equivalents over the period. $43,397K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Revenue | 540,343 | - |
| Cost of goods sold | 257,929 | - |
| Research and development | 41,057 | - |
| Sales and marketing | 77,495 | - |
| General and administrative | 126,563 | - |
| Total costs and operating expenses | 503,044 | - |
| Other income, net | 5,971 | - |
| Income tax provision (benefit) | 7,663 | - |
| Net income | 14,911 | 20,696 |
| Depreciation and amortization | 20,009 | 38,785 |
| Amortization of debt discount and issuance costs | 12,360 | - |
| Inventory step-up amortization | 1,069 | - |
| Stock-based compensation | 8,973 | 15,648 |
| Deferred income taxes, net | -3,215 | -2,569 |
| Loss on disposal of fixed assets | - | -3,382 |
| Change in fair value of contingent consideration | -4,148 | -7,939 |
| Net unrealized foreign exchange gain | 190 | 12,253 |
| Unrealized loss on derivative contracts | - | -8,709 |
| Operating lease right of use asset amortization | 13,570 | - |
| Other adjustments and non-cash items | -2,179 | -353 |
| Accounts receivable | -7,856 | 15,158 |
| Inventories | 4,522 | 824 |
| Prepaid expenses and other current assets | 5,318 | 176 |
| Other noncurrent assets | 180 | 1,547 |
| Accounts payable | 3,194 | -8,277 |
| Accrued liabilities | 12,624 | -2,995 |
| Amortization of debt discount and issuance costs | - | 8,158 |
| Operating lease liabilities | -2,292 | -9,804 |
| Operating lease right of use asset amortization | - | -9,169 |
| Noncurrent liabilities | 637 | 256 |
| Total cash provided by operating activities | 48,099 | 43,614 |
| Acquisitions, net of cash acquired | 0 | 69,954 |
| Additions to capitalized software costs | 684 | 1,371 |
| Purchases of property, plant and equipment | 4,702 | 10,664 |
| Sale of property, plant and equipment | 0 | 42 |
| Other investing activities | 2,397 | - |
| Total cash used in investing activities | -7,783 | -81,947 |
| Proceeds from exercise of stock options | 678 | 1,464 |
| Other financing activities | - | 0 |
| Payment of tax withholding obligation on vesting of restricted stock | 824 | 7,170 |
| Repayment of convertible senior notes | 0 | - |
| Payment of earnout consideration | 93 | 9,455 |
| Total cash used in financing activities | -239 | -15,161 |
| Effect of exchange rate changes on cash and cash equivalents | -185 | 4,994 |
| Net (decrease) increase in cash and cash equivalents | 39,892 | -48,500 |
| Cash and cash equivalents at beginning of period | 757,355 | - |
| Cash and cash equivalents at end of period | 748,747 | - |
REPLIGEN CORP (RGEN)
REPLIGEN CORP (RGEN)